Bronchiolitis Obliterans Syndrome (BOS) Not Yet Recruiting Phase 2 Trials for Ruxolitinib (DB08877)

Also known as: Bronchiolitis Obliterans (BO) / Bronchiolitis Obliterans / Obliterative Bronchiolitis / Bronchiolitis Obliterans Syndrome / Obliterating fibrous bronchiolitis (disorder) / Bronchiolitis fibrosa obliterans (disorder) / Obliterative bronchiolitis (disorder)

IndicationStatusPhase
DBCOND0071683 (Bronchiolitis Obliterans Syndrome (BOS))Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05413356Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans SyndromeTreatment